zovaglutide (ZT002) / Beijing QL Biopharma - LARVOL DELTA

Once-monthly zovaglutide (ZT002) for the treatment of overweight or obesity in adults: a phase 2 study (EASD 2025) - P2 | "In overweight or obese participants, once-monthly subcutaneous zovaglutide demonstrated clinically meaningful weight loss with favorable tolerability and safety profiles over 24 weeks. These promising data support further clinical development of zovaglutide as a monthly injectable treatment for overweight/obesity."

Clinical • Late-breaking abstract • P2 data • Diabetes • Metabolic Disorders • Obesity

QL Biopharm reports Phase 2 results of a monthly dose study evaluating zovaglutide, a novel, extended half-life GLP-1 receptor agonist at EASD 2025 (PRNewswire) - "Patients who received zovaglutide at a once-monthly dose of 160 mg experienced a 13.8% reduction in body weight at 24 weeks, highly comparable to reductions observed in patients who received 80 mg every other week (12.5%). The overall safety and tolerability of zovaglutide were consistent and comparable with the GLP-1 receptor agonist class of obesity management drugs."

P2 data • Obesity

Zovaglutide (ZT002), a novel ultra long-acting GLP-1 receptor agonist improves memory function and prevents degenerative processes in Alzheimer's disease animal models (EASD 2025) - "This novel ultra long-acting GLP-1 receptor agonist delayed the progressive decline in memory function and prevented key neurodegenerative developments in AD animal models, thus suggesting that zovaglutide as a once-monthly GLP-1RA represents a novel treatment strategy for Alzheimer's disease."

Late-breaking abstract • Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - P1/2 | N=27 | Completed | Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

New P1/2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Phase II Study of ZT002 Injection With Subjects With Overweight or Obesity (clinicaltrials.gov) - P2 | N=300 | Active, not recruiting | Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

New P2 trial • Genetic Disorders • Obesity

ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1c study (EASD 2024) - "This MAD trial demonstrated biweekly treatment with ZT002 induced clinically meaningful weight loss and cardiometabolic improvements with favorable tolerability and safety profiles. Further clinical evaluation of ZT002, including monthly subcutaneous administration for overweight/obesity, is ongoing."

Clinical • Metabolic Disorders • Obesity

A SAD Study of ZT002 Injection in Healthy Participants (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of ZT002 Injection in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=28 | Enrolling by invitation | Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

New P1 trial • Genetic Disorders • Obesity

A Study of ZT002 in Healthy Participants (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: QL Biopharmaceutical Australia Pty Ltd | Not yet recruiting ➔ Recruiting | N=32 ➔ 56 | Trial completion date: Aug 2023 ➔ Apr 2024 | Trial primary completion date: Feb 2023 ➔ Dec 2023

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study of ZT002 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: QL Biopharmaceutical Australia Pty Ltd

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus